THE PROGNOSTIC VALUE OF EPIDERMAL GROWTH-FACTOR RECEPTOR (EGF-R) IN PRIMARY BREAST-CANCER - RESULTS OF A 10-YEAR FOLLOW-UP-STUDY

被引:102
作者
KLIJN, JGM [1 ]
LOOK, MP [1 ]
PORTENGEN, H [1 ]
ALEXIEVAFIGUSCH, J [1 ]
VANPUTTEN, WLJ [1 ]
FOEKENS, JA [1 ]
机构
[1] DR DANIEL DENHOED CLIN,ROTTERDAM CANC INST,DEPT STAT,3075 EA ROTTERDAM,NETHERLANDS
关键词
BREAST CANCER; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL RECEPTOR; PROGESTERONE RECEPTOR; PROGNOSIS;
D O I
10.1007/BF00666183
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a study on 214 patients with primary breast cancer (median follow-up 8.5 yr, maximum follow-up 15 yr), EGF-R was negatively correlated to estrogen receptor and progesterone receptor, whereas no association was found with age, lymph node status, and tumor size. Initially, after a follow-up of 5 yr, there was a tendency to a significant association between EGF-R levels and tumor recurrence rate (p=0.08). Patients with tumors containing intermediate levels of EGF-R experienced a longer relapse-free survival (RFS) than did patients with tumors possessing lower or higher levels of EGF-R. This effect was most pronounced in the subgroup of patients with positive axillary lymph nodes. However, after 10 yr follow-up, this association appears to be lost (p=0.28) as shown in this update. A similar phenomenon was observed for the ER. While at 5 yr follow-up ER status had significant prognostic value (p=0.01), at 10 yr follow-up this significance also appears to be lost (p=0.40). However, tumor size, lymph node status, grade, and PgR status maintained significant prognostic value by univariate analysis. Based on 40 separate studies comprising 5232 patients, the mean percentage of EGF-R positivity reported in breast cancer is 45% (range 14-91%). Nine out of 15 different studies showed in some way a significant negative association between EGF-R and RFS by univariate analysis, and 2 others showed a tendency to such a relationship. Of 7 studies applying multivariate analysis, two demonstrated an independent prognostic value of EGF-R for RFS and two others a tendency to a significant correlation, whereas three did not. It may be concluded that EGF-R status has more or less prognostic value in patients with primary breast cancer, but the prognostic power decreases with longer follow-up. Of great clinical significance is the association of EGF-R with hormone resistance. Therefore EGF-R status can be used for selection of type of treatment. Finally, EGF-R might be useful as a target for new treatment modalities.
引用
收藏
页码:73 / 83
页数:11
相关论文
共 35 条
[1]  
ALEXIEVAFIGUSCH J, 1988, CANCER-AM CANCER SOC, V61, P758, DOI 10.1002/1097-0142(19880215)61:4<758::AID-CNCR2820610421>3.0.CO
[2]  
2-T
[3]   HYDROXYAPATITE ASSAY TO MEASURE EPIDERMAL GROWTH-FACTOR RECEPTOR IN HUMAN PRIMARY BREAST-TUMORS [J].
BENRAAD, TJ ;
FOEKENS, JA .
ANNALS OF CLINICAL BIOCHEMISTRY, 1990, 27 :272-273
[4]   EXPRESSION OF EPIDERMAL GROWTH-FACTOR RECEPTOR (EGF-R) IN NON-SMALL CELL LUNG-CANCER - USE OF ARCHIVAL TISSUE AND CORRELATION OF EGF-R WITH HISTOLOGY, TUMOR SIZE, NODE STATUS AND SURVIVAL [J].
DAZZI, H ;
HASLETON, PS ;
THATCHER, N ;
BARNES, DM ;
WILKES, S ;
SWINDELL, R ;
LAWSON, RAM .
BRITISH JOURNAL OF CANCER, 1989, 59 (05) :746-749
[5]  
DEFAZIO A, 1992, J BIOL CHEM, V267, P18008
[6]  
FITZPATRICK SL, 1984, CANCER RES, V44, P3448
[7]  
FOEKENS JA, 1989, CANCER RES, V49, P7002
[8]   PROGNOSTIC VALUE OF EPIDERMAL GROWTH-FACTOR RECEPTOR IN NODE-POSITIVE BREAST-CANCER [J].
GRIMAUX, M ;
ROMAIN, S ;
REMVIKOS, Y ;
MARTIN, PM ;
MAGDELENAT, H .
BREAST CANCER RESEARCH AND TREATMENT, 1989, 14 (01) :77-90
[9]  
HARRIS AL, 1990, CANCER CELL-MON REV, V2, P321
[10]  
KIENHUIS CBM, 1991, CLIN CHEM, V37, P1749